Equities analysts forecast that Exact Sciences Corporation (NASDAQ:EXAS) will announce ($0.31) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Exact Sciences Corporation’s earnings. The lowest EPS estimate is ($0.34) and the highest is ($0.22). Exact Sciences Corporation posted earnings per share of ($0.36) in the same quarter last year, which indicates a positive year-over-year growth rate of 13.9%. The company is expected to announce its next earnings report on Wednesday, October 25th.

On average, analysts expect that Exact Sciences Corporation will report full year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.28) to ($1.01). For the next fiscal year, analysts expect that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.04) to ($0.49). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Exact Sciences Corporation.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The firm had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million.

Several brokerages recently issued reports on EXAS. Canaccord Genuity reissued a “buy” rating and issued a $60.00 price target (up previously from $45.00) on shares of Exact Sciences Corporation in a report on Tuesday. Zacks Investment Research raised Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research note on Tuesday, September 26th. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 target price (up previously from $45.00) on shares of Exact Sciences Corporation in a research note on Thursday, September 21st. BidaskClub raised Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th. Finally, Vetr downgraded Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $38.66 target price on the stock. in a research note on Thursday, August 3rd. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $43.11.

Exact Sciences Corporation (NASDAQ:EXAS) opened at 48.13 on Friday. The company’s 50-day moving average price is $43.08 and its 200-day moving average price is $34.95. The firm’s market cap is $5.73 billion. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $50.65.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/06/zacks-brokerages-anticipate-exact-sciences-corporation-exas-will-post-earnings-of-0-31-per-share.html.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction on Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at approximately $782,722.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $1,373,063.40. Following the transaction, the senior vice president now owns 64,991 shares in the company, valued at $3,064,975.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 237,444 shares of company stock worth $10,412,421. 4.00% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of EXAS. Russell Investments Group Ltd. increased its position in shares of Exact Sciences Corporation by 113.5% during the 1st quarter. Russell Investments Group Ltd. now owns 119,482 shares of the medical research company’s stock valued at $2,822,000 after purchasing an additional 63,519 shares during the period. Bank of New York Mellon Corp increased its position in shares of Exact Sciences Corporation by 32.4% during the 1st quarter. Bank of New York Mellon Corp now owns 646,758 shares of the medical research company’s stock valued at $15,275,000 after purchasing an additional 158,347 shares during the period. Ameriprise Financial Inc. increased its position in shares of Exact Sciences Corporation by 11.0% during the 1st quarter. Ameriprise Financial Inc. now owns 240,030 shares of the medical research company’s stock valued at $5,683,000 after purchasing an additional 23,804 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Exact Sciences Corporation by 113.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 177,118 shares of the medical research company’s stock valued at $4,184,000 after purchasing an additional 94,268 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in shares of Exact Sciences Corporation by 455.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock valued at $216,000 after purchasing an additional 7,484 shares during the period. Institutional investors own 85.23% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on Exact Sciences Corporation (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.